loading page

Study on the Efficacy and Mechanism of Action of Ginsenoside Rg3 on Rats with Radiation Proctitis
  • +3
  • Xuxia Li,
  • Lili Lin,
  • Jiuju Dai,
  • Xiaoyu Duan,
  • Tingting Hu,
  • Hongyi Cai
Xuxia Li
Gansu University of Traditional Chinese Medicine
Author Profile
Lili Lin
Suqian First People’s Hospital
Author Profile
Jiuju Dai
Gansu University of Traditional Chinese Medicine
Author Profile
Xiaoyu Duan
Gansu Provincial Hospital
Author Profile
Tingting Hu
Gansu Provincial Hospital
Author Profile
Hongyi Cai
Gansu Provincial Hospital

Corresponding Author:[email protected]

Author Profile

Abstract

Radiation proctitis (RP) refers to rectal injury caused by radiation treatment of pelvic and retroperitoneal malignancies, which seriously affects the treatment prognosis and life quality of cancer patients. However, effective medicine for treating RP has not found yet. Ginsenoside Rg3 (GRg3) is a tetracyclic triterpene saponin monomer, which is the main bioactive component of ginseng extract. In this study, we found that GRg3 significantly improved the general condition and histopathological damage on RP rats. In addition, it has been found out that GRg3 decreased the levels of pro-inflammatory factors (TNF-α) and increased the levels of anti-inflammatory factors (IL-4, IL-10). Meanwhile, RT-qPCR and Western blot assays showed that GRg3 significantly inhibited the activation of NF-κB and Caspase-8 signaling pathways. The results suggest that GRg3 may reduce the inflammatory response by inhibiting the NF-κB signaling pathway and improving the balance of inflammation-related factors. GRg3 may also inhibit intestinal cell apoptosis by suppressing the TNF-α/Caspase-8 signaling cascade, thereby reducing radiological rectal injury. Therefore, ginsenoside Rg3 may be a promising therapeutic agent for RP.
Submitted to Immunity, Inflammation and Disease
23 Mar 2024Review(s) Completed, Editorial Evaluation Pending
31 Mar 2024Editorial Decision: Revise Major
11 May 20241st Revision Received
15 Aug 2024Review(s) Completed, Editorial Evaluation Pending
29 Aug 2024Editorial Decision: Accept